课题基金 / 基金详情

In Vivo Function and Metabolism Evaluation of Glaucomatous RGCs by Two-Photon Scanning Laser Ophthalmology

In Vivo Function and Metabolism Evaluation of Glaucomatous RGCs by Two-Photon Scanning Laser Ophthalmology
双光子扫描激光眼科评价青光眼 RGC 的体内功能和代谢
批准号:
10660761
负责人:
Yang Hu
金额:
$64.15万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-07-01 至 2028-03-31

项目摘要

项目成果

Yang Hu的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY Glaucoma, the most common worldwide cause of irreversible blindness, is characterized by progressive dysfunction and death of retinal ganglion cells (RGCs). We recently employed confocal scanning laser ophthalmoscopy (cSLO) to successfully obtain in vivo Ca2+ imaging with mouse RGCs expressing jGCaMP7s, a genetically encoded calcium indicator. Thousands of ON, OFF, and ON-OFF RGCs with characteristic responses to light stimulation are readily detected in living animals through this non-invasive in vivo imaging platform. Here we seek to develop a more advanced, first-of-its-kind two-photon (2P)-SLO platform with patterned stimulation and multiple detection channels. Through a multidisciplinary collaboration with expertise in in vivo optical imaging, RGC pathophysiology, and retinal neural circuitry and visual processing, we will use complementary imaging techniques and state-of-the-art analysis protocols to understand naïve RGC physiology in real time. We recently extended our original mouse silicone oil-induced pupillary blocking and ocular hypertension (SOHU) model to recapitulate phenotypes of two forms of glaucoma: a chronic model with moderate IOP elevation and mild RGC neurodegeneration; and an acute model with greatly elevated IOP and severe neurodegeneration. Importantly, SO removal reduces IOP to normal almost immediately, allowing better exploration of the effects of IOP lowering treatment and combined treatment with neuroprotection strategies. Thus, we will determine the longitudinal functional and metabolic changes of glaucomatous RGCs, under clinically relevant models, both before and after IOP normalization and/or neuroprotective treatments. These data will deepen our understanding of the pathophysiology of glaucoma, towards finding much-sought biomarkers to better predict progression, and create more relevant endpoints for developing treatment to restore RGC physiology in vivo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms of peroxisome proliferator-activated receptor-alpha regulation in peridontitis
  • 批准号:
    10915090
  • 项目类别:
  • 资助金额:
    $49.75万
  • 财政年份:
    2023
  • 负责人:
    Yang Hu
  • 依托单位:
Optineurin dysfunction induces neurodegeneration in normal tension glaucoma by a novel molecular mechanism
  • 批准号:
    10372873
  • 项目类别:
  • 资助金额:
    $54.57万
  • 财政年份:
    2022
  • 负责人:
    Yang Hu
  • 依托单位:
Optineurin dysfunction induces neurodegeneration in normal tension glaucoma by a novel molecular mechanism
  • 批准号:
    10557146
  • 项目类别:
  • 资助金额:
    $54.57万
  • 财政年份:
    2022
  • 负责人:
    Yang Hu
  • 依托单位:
Neuroprotection by Modulating ER Stress in Glaucoma
  • 批准号:
    10390110
  • 项目类别:
  • 资助金额:
    $15.74万
  • 财政年份:
    2021
  • 负责人:
    Yang Hu
  • 依托单位:
海外基金